Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy (original) (raw)

• Ford JM, Hait WN . Pharmacology of drugs that alter multidrug resistance in cancer Pharmacol Rev 1990 42: 155–199
  CAS Google Scholar
• Springer CJ, Niculescu-Duvaz I . Approaches to gene-directed enzyme prodrug therapy (GDEPT) Adv Exp Med Biol 2000 465: 403–409
  Article CAS Google Scholar
• Aghi M, Hochberg F, Breakefield XO . Prodrug activation enzymes in cancer gene therapy J Gene Med 2000 2: 148–164
  Article CAS Google Scholar
• Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 1992 256: 1550–1552
  Article CAS Google Scholar
• Huber BE et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase Cancer Res 1993 53: 4619–4626
  CAS Google Scholar
• Mullen CA, Coale MM, Lowe R, Blaese RM . Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor Cancer Res 1994 54: 1503–1506
  CAS Google Scholar
• Bridgewater JA et al. The bystander effect of the nitro-reductase/CB1954 enzyme/prodrug sysem is due to a cell-permeable metabolite Hum Gene Ther 1997 8: 709–717
  Article CAS Google Scholar
• Marais R et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy Nat Biotech 1997 15: 1373–1377
  Article CAS Google Scholar
• Stribbling SM et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect Hum Gene Ther 2000 11: 285–292
  Article CAS Google Scholar
• Paigen K . Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology Prog Nucleic Acid Res Mol Biol 1989 37: 155–205
  Article CAS Google Scholar
• Carmeliet P, Jain RK . Angiogenesis in cancer and other diseases Nature 2000 407: 249–257
  Article CAS Google Scholar
• Rosenfeld MG et al. Biosynthesis of lysosomal hydrolases: their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution J Cell Biol 1982 93: 135–143
  Article CAS Google Scholar
• Weyel D, Sedlacek HH, Müller R, Brüsselbach S . Secreted human β-glucuronidase: a novel prodrug converting enzyme for gene therapy Gene Therapy 2000 7: 224–231
  Article CAS Google Scholar
• Kontermann RE, Muller R . Intracellular and cell surface displayed single-chain diabodies J Immunol Meth 1999 226: 179–188
  Article CAS Google Scholar
• Denzer AJ, Nabholz CE, Spiess M . Transmembrane orientation of signal-anchor proteins is affected by the folding state but not the size of the N-terminal domain EMBO J 1995 14: 6311–6317
  Article CAS Google Scholar
• Lichtenstein DL, Roberts SR, Wertz GW, Ball LA . Definition and functional analysis of the signal/anchor domain of the human respiratory syncytial virus glycoprotein G J Gen Virol 1996 77: 109–118
  Article CAS Google Scholar
• Bosslet K, Czech J, Hoffmann D . Tumor-selective prodrug activation by fusion protein-mediated catalysis Cancer Res 1994 54: 2151–2159
  CAS Google Scholar
• Bosslet K, Czech J, Hoffmann D . A novel one-step tumor-selective prodrug activation system Tumor Targetting 1995 1: 45–50
  CAS Google Scholar
• Florent JC et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy J Med Chem 1998 41: 3572–3581
  Article CAS Google Scholar
• Platel D, Bonoron-Adele S, Dix RK, Robert J . Preclinical evaluation of the cardiac toxicity of HMMR-1826, a novel prodrug of doxorubicin Br J Cancer 1999 81: 24–27
  Article CAS Google Scholar
• Bosslet K et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res 1998 58: 1195–1201
  CAS Google Scholar
• Bakinna E, Wu Z, Rosenblum M, Farquhar D . Intensely cytotoxic anthracycline prodrugs: glucuronides J Med Chem 1997 40: 4013–4018
  Article Google Scholar
• Papot S et al. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard Bioorg Med Chem Lett 2000 10: 1835–1837
  Article CAS Google Scholar
• de Bont DB et al. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT Bioorg Med Chem 1997 5: 405–414
  Article CAS Google Scholar
• Haisma HJ et al. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer Br J Cancer 1992 66: 474–478
  Article CAS Google Scholar
• Haisma HJ et al. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy Blood 1998 92: 184–190
  CAS Google Scholar
• Houba PH et al. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy Biochem Pharmacol 1996 52: 455–463
  Article CAS Google Scholar
• Leu YL, Roffler SR, Chern JW . Design and synthesis of water-soluble glucuroide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT) J Med Chem 1999 42: 3623–3628
  Article CAS Google Scholar
• Wang SM et al. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy Cancer Res 1992 52: 4484–4491
  CAS PubMed Google Scholar
• Waxman DJ, Chen L, Hecht JE, Jounaidi Y . Cytochrome P450-based cancer gene therapy: recent advances and future prospects Drug Metab Rev 1999 31: 503–522
  Article CAS Google Scholar
• Lucibello FC et al. Periodic cdc25C transcription is mediated by a novel cell cycle-regulated represssor element (CDE) EMBO J 1995 14: 132–142
  Article CAS Google Scholar